Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific NIR Stent With SOX Inventory Sufficient For Relaunch

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific has sufficient inventory of its modified NIR coronary stent with the SOX delivery system to support relaunch the week of March 20, the firm reported March 16 in announcing FDA approval of a premarket approval application supplement. Product manufacturing and shipments to Japan commenced earlier this year following approval by the Japanese Ministry of Health in December.

You may also be interested in...



Boston Scientific Seeks To Defend Rapid-Exchange Patents In U.S., Abroad

Boston Scientific is seeking to defend the intellectual property gained through its $2.1 bil. Schneider buy in 1998 by filing suit against Medtronic claiming infringement of a rapid-exchange catheter patent.

Boston Scientific Seeks To Defend Rapid-Exchange Patents In U.S., Abroad

Boston Scientific is seeking to defend the intellectual property gained through its $2.1 bil. Schneider buy in 1998 by filing suit against Medtronic claiming infringement of a rapid-exchange catheter patent.

Boston Scientific's Strong Japanese Sales Help Offset U.S., EU Declines

Emerging stent and balloon markets in Japan gave Boston Scientific its fourth consecutive quarter of market leadership in those businesses, as revenues grew 47% over the fourth quarter of 1998, the firm reported during a Feb. 8 teleconference.

Related Content

UsernamePublicRestriction

Register

MT013101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel